$Alterity Therapeutics (ATHE.US)$Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics (NASDAQ: ATHE) has reported positive interim data from its ATH434-202 Phase 2 clinical trial for multiple system atrophy (MSA). Key findings include:
▪️43% of participants showed improvement in daily living activities
29% had stable or improved neurological symptoms
▪️Objective biomarkers demonstrated improvement consist...